TCRT Alaunos Therapeutics Inc Stock Price Quote NASDAQ

Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. Compare
TCRT’s historical performance
against its industry peers and the overall market.

More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX. TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

Related News TCRT

In the latest trading session, Alaunos (TCRT) closed at $0.70, marking a -1.71% move from the previous day. In the latest trading session, Alaunos (TCRT) closed at $0.66, marking a -0.75% move from the previous day. Alaunos (TCRT) closed at $0.64 in the latest trading session, marking a -1.54% move from the prior day. Alaunos (TCRT) closed at $0.60 in the latest trading session, marking a +0.81% move from the prior day. In the latest trading session, Alaunos (TCRT) closed at $0.50, marking a +1.02% move from the previous day.

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered https://1investing.in/ an upward trend or a buy. According to 4 analysts, the average rating for TCRT stock is “Buy.” The 12-month stock price forecast is $3.0, which is an increase of 2,309.64% from the latest price. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.

Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research free leads and data to our policies on content and your personal data. TCRT’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns.

• 7 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for TCR2 Therapeutics in the last twelve months.
• One share of TCRT stock can currently be purchased for approximately $0.12.
• HOUSTON–(BUSINESS WIRE)– #antibodies–CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced the formation of a scie…
• These returns cover a period from January 1, 1988 through July 31, 2023.

Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods.

Major Holders

3 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Alaunos Therapeutics in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “hold” TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.

• Use these ten stocks to generate a safe and reliable source of investment income.
• TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy.
• There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
• The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
• The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Alaunos (TCRT) closed at $0.60 in the latest trading session, marking a -1.64% move from the prior day. Industry leader brings more than 25 years of scientific leadership and expertise in T-cell therapy development Industry leader brings more than 25 years of scientific leadership and expertise in T-cel… The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success.

CellChorus Announces Scientific Advisory Board

The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Use these ten stocks to generate a safe and reliable source of investment income. MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Style is calculated by combining value and growth scores, which are first individually calculated. Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction. Alaunos (TCRT) closed the most recent trading day at $0.55, moving -0.54% from the previous trading session. HOUSTON–(BUSINESS WIRE)– #antibodies–CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced the formation of a scie…

This suggests a possible upside of 232.0% from the stock’s current price. View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts. 7 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for TCR2 Therapeutics in the last twelve months. The consensus among Wall Street analysts is that investors should “hold” TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.

One share of TCRR stock can currently be purchased for approximately $1.48. Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. One share of TCRT stock can currently be purchased for approximately $0.12. Alaunos Therapeutics’ stock is owned by a variety of retail and institutional investors. Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma. The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.

Services

The information agency “Marketing Sentinel” was established at the end of 2004. Upgrade to MarketBeat All Access to add more stocks to your watchlist. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.